Another outstanding achievement for Henrik Watz, MD, PhD, and our team in Ahrensburg, Germany! They led enrollment for a global chronic obstructive pulmonary disease (COPD) trial, more than doubling the enrollment of the next highest-performing site. Congratulations to Dr. Watz and our Ahrensburg team! Learn more about our respiratory capabilities >
Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, presented late-breaking data for Iqirvo® (elafibranor), Ipsen’s treatment for primary biliary cholangitis (PBC), at American Association for the Study of Liver Diseases (AASLD). “Over three years, Iqirvo data suggest sustained efficacy and support the safety profile of the medicine,” said Dr. Kowdley. “Importantly, when patients tell me they … Read more
Over the past decade, Germany’s share of global clinical trial activities has dropped year on year. The country accounted for just 3.9% of trials in 2021, down from 7.2% in 2012. Late last year, the German Government published its National Pharma Strategy, which is designed to reverse this trend. Aiming to revitalize the country’s pharmaceutical … Read more
Velocity enrolled more than 8,000 participants in clinical trials in October, marking our highest-ever enrollment in a single month. This required many long hours and thoughtful solutioning from so many across the organization. A special thank you to our site staff and Recruitment team, who continuously rise to every challenge and keep patient care and … Read more
As of today, VISION technology has now contributed to over 7,000 randomizations across the U.S. and Europe. At just a year since its launch, VISION is already making clinical trials more accessible to all on a global scale. We’re proud of the impact our team and technology are making in advancing clinical research. Here’s to … Read more
Velocity has been recognized among the Top 50 Operations Teams at the 2024 OnCon Icon Awards! This award is especially meaningful because it’s based on peer and community votes, reflecting the operational excellence our team continues to build as we scale globally. Thank you to OnConferences, to everyone who voted, and to our exceptional team … Read more
At the beginning of September, Velocity Clinical Research topped Business North Carolina’s 2024 Fast 40 list. It was our third time receiving the award, which recognizes the fastest-growing mid-market businesses in the state. For a clinical trials organization to achieve this level of scale is notable. The clinical trials sector in the US is typically … Read more
In his latest article for the Association of Clinical Research Professionals (ACRP), Paul Evans outlines how integrated site organizations can pave the way for AI adoption and generate tangible value for the industry. For sites, investigators, and patients, Gen AI has the potential to streamline recruitment, reduce manual labor, and accelerate trial processes. By leveraging … Read more
The pandemic left many notable developments in its wake, not least the increased focus on improving diversity in clinical trials. This issue was thrust into the spotlight during Operation Warp Speed — the accelerated development of a COVID-19 vaccine in the U.S. — and is one Jerome Adams, MD, MPH, who served as U.S. General … Read more
As Nick Spittal states in this Advarra press release, membership in the Gene Therapy Ready (GTR) site network “allows Velocity to start studies over a month faster and provides a meaningful credential and important validation that increases sponsors’ confidence in our specialized capabilities to conduct complex clinical research safely.” All Velocity sites are fully prepared … Read more